Axsome Therapeutics, Inc.
AXSM
$158.88
$1.010.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.62% | 13.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.62% | 13.96% | |||
| Cost of Revenue | 3.50% | -11.42% | |||
| Gross Profit | 15.46% | 16.46% | |||
| SG&A Expenses | 12.69% | 15.32% | |||
| Depreciation & Amortization | 0.00% | 1.13% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.78% | 4.65% | |||
| Operating Income | -9.42% | 26.54% | |||
| Income Before Tax | 40.44% | 3.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.53% | 1.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.53% | 1.55% | |||
| EBIT | -9.42% | 26.54% | |||
| EBITDA | -9.96% | 27.63% | |||
| EPS Basic | 40.26% | 2.69% | |||
| Normalized Basic EPS | -7.95% | 27.86% | |||
| EPS Diluted | 40.26% | 2.69% | |||
| Normalized Diluted EPS | -7.95% | 27.86% | |||
| Average Basic Shares Outstanding | 1.22% | 1.17% | |||
| Average Diluted Shares Outstanding | 1.22% | 1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||